RecruitingPhase 1NCT06830031

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

Studying Epstein-Barr virus-positive diffuse large B-cell lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shanghai Exuma Biotechnology Ltd.
Principal Investigator
Liang Huang, MD
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Intervention
C402-CD19-CAR(biological)
Enrollment
18 enrolled
Eligibility
18-75 years · All sexes
Timeline
20252026

Study locations (1)

Collaborators

Institute of Hematology & Blood Diseases Hospital, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06830031 on ClinicalTrials.gov

Other trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma

← Back to all trials